Skip to main content

Psoriatic arthritis

psoriatic.PIP_.JPG

Biologic Persistence in Psoriatic Arthritis and Psoriasis

May 19, 2022

Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.

Read Article
SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

May 18, 2022

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
FDA.Safety.jpg

Bimekizumab Development Delayed by FDA

May 16, 2022

UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).

Read Article
Methotrexate

Can You Reduce Frequency of Methotrexate Monitoring?

May 12, 2022

Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an

Read Article
We had a great TNR this week. Playback now available in case you missed it. This webinar presented excerpts from these lectures along with Q & A Psoriatic Arthritis Guidelines Drug Targeting in PsA PsA Registries and Real World Data https://t.co/al17KLQm0j https://t.co/O4SvMU37Lg
Dr. John Cush @RheumNow( View Tweet )
May 12, 2022
Making You the Expert of You! (Smart Rules for Patients) You’ve scheduled an appointment with your medical provider - how do you make the most of it?https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3
Dr. John Cush @RheumNow( View Tweet )
May 12, 2022
psoriasis,arm,hand,rash,elbow

Bimekizumab's Favorable Safety Profile in Psoriasis

May 11, 2022

A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.

Read Article
PsA,Pod,RNL

RNL 2022: Psoriatic Arthritis Advances

May 11, 2022

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.



This webinar presented exerpts from these lectures along with audience Q & A



  • Psoriatic Arthritis Guidelines Arthur Kavanaugh, MD

  • Drug Targeting in PsA Bruce Kirkham
Read Article
Interested in what we covered in the month of April? You can find all our PsA content at the link below. What was your biggest takeaway from our PsA All the Way campaign?https://t.co/hl0HKggULj https://t.co/O1QMibJ4qA
Dr. John Cush @RheumNow( View Tweet )
May 11, 2022
Patient,instruction

Making You the Expert of You! (Smart Rules for Patients)

May 10, 2022

You’ve scheduled an appointment with your medical provider - how do you make the most of it? We've gathered these tips and suggestions to share with patients.

Read Article
TOMORROW! Register for our 5/10 Tuesday Night Rheumatology on PsA Advances. This webinar will feature highlights from: PsA Guidelines Arthur Kavanaugh, MD Drug Targeting in PsA Bruce Kirkham, MD PsA Registries and Real World Data Alexis Ogdie, MDhttps://t.co/0fNuHz6wVy https://t.co/KssNJ41Wqz
Dr. John Cush @RheumNow( View Tweet )
May 09, 2022
Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/U5wAQdWLdC https://t.co/QfoaogDeun
Dr. John Cush @RheumNow( View Tweet )
May 08, 2022
Large Korean population study compares pts w/ palmoplantar psoriasis vs psoriasis and PPP pts have more risk for ankylosing spondylitis (aOR 1.37) & Graves dz (aOR 1.4) but lower risk for PsA (aOR 0.54), SLE (0.67); Sjögren (0.70); vitiligo (0.53) https://t.co/0fv2vnFBPf https://t.co/PJMagIeZ2F
Dr. John Cush @RheumNow( View Tweet )
May 07, 2022
Study of 17 homeless RA or PsA pts - less clinic access (80% vs 91%), more ED use (20 vs 5), less DMARDs (43% vs 100%), more steroids (29% vs 0%); 83% unable to work due to health. Greatest need - dental , PT, knee surgery, employment & housing https://t.co/VHnTR0MTkr https://t.co/JDZTELz2qB
Dr. John Cush @RheumNow( View Tweet )
May 06, 2022
There is 1.4 million transgender persons in the US. ACP has published a guideline "Care of the Transgender Patient" addressing health disparities, certain cancers, substance abuse, mental health conditions, infections, and chronic diseases. https://t.co/AoBeOzv9YH https://t.co/jKabVELPxH
Dr. John Cush @RheumNow( View Tweet )
May 06, 2022
Study of 13 European registries on durability/effect of interleukin-17 (IL-17) inhibition with secukinumab: among 2,017 PsA on secukinumab, retention rates were 86% and 76% at 6 and 12 mos, with 12 mo remission rate of 11% to 16% https://t.co/03sJBSbUy6

Dr. John Cush @RheumNow( View Tweet )

May 04, 2022
Neural networks of high-res quantitative CT (HR-pQCT) scans allowed for 3D imaging of MCP2 to differentiate normals from #RA & #PsA. 932 of 617 ppts correct AuROC for HC 82%, RA 75%, PsA 68%. UA pts read as 86% RA,11% PsA, & 3% HC https://t.co/wSQgllYgug https://t.co/yA6g55SpeC
Dr. John Cush @RheumNow( View Tweet )
May 04, 2022
Thanks so much to all who contributed to April's PsA All the Way campaign on RheumNow. You can find all our PsA content at the link below. Did you learn anything new about PsA from our coverage?https://t.co/Mo7Yf2cu4i https://t.co/LvpuLtF4Mv
Dr. John Cush @RheumNow( View Tweet )
May 04, 2022
Rheumatologic diagnosis through hand exam by Dr. Sarah Chung @ACPinternists #rheumatology #rheumtwitter #MedEd #rheumatoidarthritis #BJHM #Hospitalmedicine #IM2022 #MedTwitter 👇🏽 https://t.co/qR4zNa4NcX
Brown Journal of Hospital Medicine @BrownJHM( View Tweet )
May 03, 2022
Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/NiPTbknD57 https://t.co/HOC2Bev4R6
Dr. John Cush @RheumNow( View Tweet )
May 02, 2022
We completed a whole month of super-charged, focused coverage & education on #PsA.THANKS to the many mavens who contributed! In PSA - "Unless someone like you cares a whole awful lot, nothing is going to get better. It’s not." -Dr. Seuss, The Lorax https://t.co/Y58klwbS4V https://t.co/f2pnuypwyr
Dr. John Cush @RheumNow( View Tweet )
May 02, 2022
Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion about two important studies.https://t.co/RjFRFt6oJQ https://t.co/zOxCDC1atS
Dr. John Cush @RheumNow( View Tweet )
May 01, 2022
RheumNow Podcast square

$30 Billion and Counting (4.29.2022)

Apr 29, 2022

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Read Article
Perplexing Oligoarthritis, +FHx, But no psoriasis QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022https://t.co/ljZ1cStNTy https://t.co/8RMFFWjDEP
Dr. John Cush @RheumNow( View Tweet )
Apr 27, 2022
TNRPSA,0426

PsA Journal Club - Fecal Transplant & H2H IXE vs ADA

Apr 27, 2022

Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion  about two important studies.

Read Article
×